GREENWICH LIFESCIENCES, INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
GREENWICH LIFESCIENCES, INC. (GLSI) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 12.94 million shares for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-21.
Discontinued › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-03-21
- GREENWICH LIFESCIENCES, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 13.30M shares, a 9.81% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 12.97M shares, a 47.57% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 12.90M shares, a 50.17% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-03-31 was 12.80M shares, a 50.65% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 12.94M shares, a 36.27% increase from fiscal 2020.
- GREENWICH LIFESCIENCES, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 9.50M shares, a 320.69% increase from fiscal 2019.
- GREENWICH LIFESCIENCES, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 2.26M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-12-31 | 13.30M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | 13.13M shares derived: average of 2 quarters · filed 2022-03-21 | 13.05M shares derived: average of 3 quarters · filed 2022-03-21 | 12.94M shares 10-K · filed 2022-03-21 |
| 2021-09-30 | 12.97M shares 10-Q · filed 2021-11-15 | 12.93M shares derived: average of 2 quarters · filed 2021-11-15 | 12.83M shares 10-Q · filed 2021-11-15 | 12.69M shares derived: average of 4 quarters · filed 2022-03-21 |
| 2021-06-30 | 12.90M shares 10-Q · filed 2021-08-13 | 12.79M shares 10-Q · filed 2021-08-13 | 12.60M shares derived: average of 3 quarters · filed 2022-03-21 | 11.65M shares derived: average of 4 quarters · filed 2022-03-21 |
| 2021-03-31 | 12.80M shares 10-Q · filed 2021-05-20 | 12.46M shares derived: average of 2 quarters · filed 2022-03-21 | 11.23M shares derived: average of 3 quarters · filed 2022-03-21 | 10.57M shares derived: average of 4 quarters · filed 2022-03-21 |
| 2020-12-31 | 12.11M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | 10.45M shares derived: average of 2 quarters · filed 2022-03-21 | 9.83M shares derived: average of 3 quarters · filed 2022-03-21 | 9.50M shares 10-K · filed 2022-03-21 |
| 2020-09-30 | 8.79M shares 10-Q · filed 2021-11-15 | 8.69M shares derived: average of 2 quarters · filed 2021-11-15 | 8.63M shares 10-Q · filed 2021-11-15 | 8.55M shares derived: average of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | 8.59M shares 10-Q · filed 2021-08-13 | 8.55M shares 10-Q · filed 2021-08-13 | 8.47M shares derived: average of 3 quarters · filed 2021-08-13 | 6.43M shares derived: average of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | 8.50M shares 10-Q · filed 2021-05-20 | 8.42M shares derived: average of 2 quarters · filed 2021-05-20 | 5.71M shares derived: average of 3 quarters · filed 2021-05-20 | |
| 2019-12-31 | 8.33M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | 4.31M shares derived: average of 2 quarters · filed 2021-03-31 | 2.26M shares 10-K · filed 2021-03-31 | |
| 2019-09-30 | 291.78K shares 10-Q · filed 2020-11-16 | 232.92K shares 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |